$ULBI

ULBI SEC Filings - Ultralife 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Ultralife (ULBI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It highlights recent filings, such as a Form 4 detailing insider purchases by director Bradford T. Whitmore, and provides information on Ultralife's financial performance and corporate governance. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.

Original reporting
Published May 23, 2026, 2:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 23, 2026, 2:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ULBI
Neutral
medium confidence
Mentioned
$ULBI
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$ULBINeutralLow
01

Why it matters

The filings suggest stability with no immediate red flags; insider purchase may indicate confidence but is not a guarantee of future performance.

02

Market read

While relevant for investors and analysts focusing on Ultralife, the filings have limited impact on broader market movements.

03

What to watch

Market reaction may be muted if overall market conditions are volatile or if broader sector trends dominate.

Timing: long-term

Background

Ultralife's recent SEC filings include financial reports and insider trading disclosures, providing transparency into its corporate activities.

Company-level read

Ticker impact

$ULBINeutralMedium confidence
Context

SEC filings provide detailed insights into Ultralife's financial health and corporate governance, which are relevant for long-term investors and analysts.

Expected impact

Minimal short-term price movement expected; long-term impact depends on upcoming financial performance.

Evidence & confidence

SEC filings are standard disclosures; insider purchases can signal confidence but are not definitive indicators of stock movement.

Market effects

The filings relate to manufacturing and technology sectors, with no immediate sector-wide disruptions indicated.

Limited regional impact; filings are company-specific.

Low; company-specific disclosures generally do not influence global markets.

Counterpoint

Some investors might interpret insider purchases as a sign of undervaluation, potentially offering a buying opportunity.

Key entities

  • Ultralife Corporation

    A manufacturer providing power solutions and communications equipment.

  • Bradford T. Whitmore

    Director of Ultralife who made an insider purchase.

Related articles

$ULBIMedAI 8/10

Ultralife (ULBI) Q2 2026 Earnings Call Transcript

Ultralife (ULBI) reported Q2 FY2026 revenue of $47.9 million, down 1.3% year over year, with GAAP EPS of $0.15. Gross margin rose to 28.9% on a 500 bps increase, aided by a $1.1 million IEEPA tariff refund. Backlog hit a record $117.5 million, up 39% from a year earlier, and July backlog neared $130 million.

$ULBIMed

ULTRALIFE CORP (ULBI): Results of Operations and Financial Condition

ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following results: ● Sales of $47.9 million compared to $48.6 mil

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.